Document is current
Any future updates will be listed below
-
Authors
Beltrán-Visiedo, Manuel https://orcid.org/0000-0002-7977-8020
Soler-Agesta, Ruth https://orcid.org/0000-0003-3153-389X
Sarosiek, Kristopher A. https://orcid.org/0000-0002-4618-5085
Green, Douglas R. https://orcid.org/0000-0002-7332-1417
Galluzzi, Lorenzo https://orcid.org/0000-0003-2257-8500
- License Information
-
More Information
Article History
Accepted: 30 May 2025
First Online: 2 July 2025
Competing interests
: D.R.G. is/has been holding research contracts with Amgen and has received consulting/advisory honoraria for Sonata Pharmaceuticals, Ventus Pharmaceuticals and ASHA Therapeutics. L.G. is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, AbbVie and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. The other authors have no conflicts of interest to declare.
